NEW YORK – CareDx said on Wednesday that it has acquired European transplant surveillance software firm BFS Molecular.
Financial terms of the deal were not disclosed.
BFS Molecular uses next-generation sequencing data to track the health of transplanted organs and stem cells over time. It offers the StemScan assay for post-transplant chimerism detection in allogeneic hematopoietic stem cell transplant patients, and the OrganScan assay for donor-derived DNA detection in solid organ transplant patients. The NGS data from these assays is then processed and analyzed by the firm's Graftrack software, which also allows for the entry of other monitoring results alongside those of the StemScan or OrganScan assays. According to BFS Molecular's website, this produces a comprehensive picture of each transplant patient over time.
The acquisition of the Graftrack software — as well as BFS Molecular's algorithm development capabilities for NGS transplant surveillance products — will add value to CareDx's portfolio, particularly to its AlloSeq cfDNA NGS-based transplant monitoring test and its AlloSeq HCT chimerism testing kit, the company said.
As a result of the acquisition, BFS Molecular Cofounder and CEO Tim Hague will join CareDx as vice president of global lab products software. Hague previously served as CEO of Omixon, a developer of NGS HLA typing products.
"With BFS Molecular now joining CareDx, we are adding to our bioinformatics and transplant surveillance software expertise and solidifying our presence in Europe," CareDx CEO Reg Seeto noted in a statement.